Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis

Autor: Vervoort, Stephin J, De Jong, Olivier G, Roukens, M Guy, Frederiks, Cynthia L, Vermeulen, Jeroen F, Lourenço, Ana Rita, Bella, Laura, Vidakovic, Ana Tufegdzic, Sandoval, José L, Moelans, Cathy, Van Amersfoort, Miranda, Dallman, Margaret J, Bruna, Alejandra, Caldas, Carlos, Nieuwenhuis, Edward, Van Der Wall, Elsken, Derksen, Patrick, Van Diest, Paul, Verhaar, Marianne C, Lam, Eric W-F, Mokry, Michal, Coffer, Paul J

Publikováno v: eLife, 7. eLife Sciences Publications
eLife
eLife, Vol 7 (2018)

The expression of the transcription factor SOX4 is increased in many human cancers, however, the pro-oncogenic capacity of SOX4 can vary greatly depending on the type of tumor. Both the contextual nature and the mechanisms underlying the pro-oncogeni

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8161147ea70b0deedb50c49a55d62663
https://www.repository.cam.ac.uk/handle/1810/288767

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation.

Autor: Batra RN; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK.; German Cancer Research Center (DKFZ), Heidelberg, 69120, Germany., Lifshitz A; Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel., Vidakovic AT; Mechanisms of Transcription Laboratory, The Francis Crick Institute, London, UK., Chin SF; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK., Sati-Batra A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK., Sammut SJ; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Provenzano E; Cancer Research UK Cambridge Centre, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Ali HR; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK.; Cancer Research UK Cambridge Centre, Cambridge, UK.; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Dariush A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK., Bruna A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK., Murphy L; Research Institute in Oncology and Hematology, Winnipeg, Manitoba, Canada., Purushotham A; School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Ellis I; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK., Green A; Division of Cancer and Stem Cells, School of Medicine, University of Nottingham and Nottingham University Hospital NHS Trust, Nottingham, UK., Garrett-Bakelman FE; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA.; Department of Medicine, University of Virginia School of Medicine, Charlottesville, VA, USA.; Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA, USA., Mason C; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA., Melnick A; Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, USA., Aparicio SAJR; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada., Rueda OM; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK.; Department of Oncology, University of Cambridge, Cambridge, UK., Tanay A; Department of Computer Science and Applied Mathematics, and Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel. amos.tanay@weizmann.ac.il., Caldas C; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.; Department of Oncology, University of Cambridge, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.; Cancer Research UK Cambridge Centre, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.; Cambridge Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. Carlos.Caldas@cruk.cam.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2021 Sep 13; Vol. 12 (1), pp. 5406. Date of Electronic Publication: 2021 Sep 13.